Form 4: Biora Therapeutics Director Acquires Stock Options and Restricted Stock Units

Director Jeffrey D. Alter acquired 12,500 stock options and 12,500 restricted stock units in Biora Therapeutics, Inc.

Summary

• On June 5, 2024, Jeffrey D. Alter, a director of Biora Therapeutics, Inc., acquired 12,500 shares of common stock and 12,500 stock options.
• The common stock was acquired through restricted stock units.
• The restricted stock units vest in full on the earlier of the first anniversary of the grant date or the date of the Issuer's 2025 annual meeting of stockholders, subject to continued service.
• The stock options have an exercise price of $0.70 and expire on June 5, 2034.
• The stock options also vest in full on the earlier of the first anniversary of the grant date or the date of the Issuer's 2025 annual meeting of stockholders, subject to continued service.
• Following the transaction, Alter directly owns 31,546 shares of common stock and 12,500 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating insider transactions, which can be interpreted as a positive sign of confidence but doesn't provide enough information to be strongly positive.

Positives

• The acquisition of stock options and restricted stock units by a director may signal confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon the director's continued service to the Issuer.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders.

Stakeholder Impact

• The acquisition of stock options and restricted stock units by a director may be viewed positively by shareholders.

Key Dates

Keywords

Biora Therapeutics, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, BIOR